Germany · Delayed Price · Currency is EUR Biofrontera AG Statistics
Total Valuation
Biofrontera AG has a market cap or net worth of EUR 16.23 million. The enterprise value is 11.98 million.
| Market Cap | 16.23M |
| Enterprise Value | 11.98M |
Important Dates
The last earnings date was Tuesday, September 30, 2025.
| Earnings Date | Sep 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 6.08M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +230.58% |
| Shares Change (QoQ) | +1.43% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 7.20% |
| Float | 1.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.68 |
| PB Ratio | 0.83 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.43 |
| EV / Sales | 0.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.76, with a Debt / Equity ratio of 0.03.
| Current Ratio | 1.76 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -439.50 |
Financial Efficiency
Return on equity (ROE) is -5.24% and return on invested capital (ROIC) is -11.42%.
| Return on Equity (ROE) | -5.24% |
| Return on Assets (ROA) | -7.77% |
| Return on Invested Capital (ROIC) | -11.42% |
| Return on Capital Employed (ROCE) | -17.78% |
| Revenue Per Employee | 272,655 |
| Profits Per Employee | -11,080 |
| Employee Count | 88 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 1.11 |
Taxes
| Income Tax | -2.37M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.76% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -3.76% |
| 50-Day Moving Average | 2.69 |
| 200-Day Moving Average | 2.54 |
| Relative Strength Index (RSI) | 38.02 |
| Average Volume (20 Days) | 1,775 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biofrontera AG had revenue of EUR 23.72 million and -964,000 in losses. Loss per share was -0.13.
| Revenue | 23.72M |
| Gross Profit | 18.08M |
| Operating Income | -3.52M |
| Pretax Income | -3.33M |
| Net Income | -964,000 |
| EBITDA | -3.27M |
| EBIT | -3.52M |
| Loss Per Share | -0.13 |
Balance Sheet
The company has 4.90 million in cash and 651,000 in debt, giving a net cash position of 4.25 million.
| Cash & Cash Equivalents | 4.90M |
| Total Debt | 651,000 |
| Net Cash | 4.25M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 19.55M |
| Book Value Per Share | 3.22 |
| Working Capital | 6.66M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 76.21%, with operating and profit margins of -14.82% and -4.06%.
| Gross Margin | 76.21% |
| Operating Margin | -14.82% |
| Pretax Margin | -14.05% |
| Profit Margin | -4.06% |
| EBITDA Margin | -13.77% |
| EBIT Margin | -14.82% |
| FCF Margin | n/a |
Dividends & Yields
Biofrontera AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -230.58% |
| Shareholder Yield | -230.58% |
| Earnings Yield | -5.94% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 14, 2024. It was a reverse split with a ratio of 0.047619.
| Last Split Date | May 14, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.047619 |
Scores
Biofrontera AG has an Altman Z-Score of -4.34 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.34 |
| Piotroski F-Score | 1 |